ZYNRELEF Drug Insight and Market Forecast - 2032

“ZYNRELEF Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ZYNRELEF for Postoperative Pain in the 7MM. A detailed picture of the ZYNRELEF for Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the ZYNRELEF for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZYNRELEF market forecast, analysis for Postoperative Pain in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Postoperative Pain.

Drug Summary

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) is a fixed-dose combination of the local anesthetic bupivacaine with the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. The drug is approved in Europe, while an NDA in the US has been resubmitted. ZYNRELEF is indicated to treat somatic-postoperative pain from small- to medium-sized surgical wounds in adults. Efficacy and safety have not been established in major surgeries, including abdominal, vascular and thoracic surgeries. The drug is designed to deliver superior pain relief while reducing the need for systemically administered pain medications, such as opioids. The inclusion of low-dose meloxicam in the drug reduces local inflammation and reverses the acidic environment caused by surgery, allowing enhanced penetration of bupivacaine into the nerves and thereby potentiating its effect.

ZYNRELEF is a fixed-dose, prolonged-release combination of bupivacaine and meloxicam. For approximately 72 h after ZYNRELEF is applied to the surgical site, it releases bupivacaine and meloxicam, which are then absorbed into the surrounding tissues. Meloxicam is believed to control tissue inflammation, thereby normalizing the pH and potentiating the effect of bupivacaine, increasing analgesia
The company anticipates the availability of ZYNRELEF to patients in Europe during 2022. Each mL of solution contains 29.25 mg of bupivacaine and 0.88 mg of meloxicam. Each vial delivers a dose of 60 mg/1.8 mg of bupivacaine/meloxicam. The maximum total dose of ZYNRELEF to be applied not recommended to exceed 400 mg/12 mg (about 14 mL).

Bupivacaine is a local anesthetic that temporarily numbs the area to which it has been applied by blocking pain signals to the brain. Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), reduces pain and inflammation and strengthens the effect of bupivacaine.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ZYNRELEF description, mechanism of action, dosage and administration, research and development activities in Postoperative Pain.
• Elaborated details on ZYNRELEF regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZYNRELEF research and development activity in Postoperative Pain details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ZYNRELEF.
• The report contains forecasted sales of ZYNRELEF for Postoperative Pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative Pain.
• The report also features the SWOT analysis with analyst views for ZYNRELEF in Postoperative Pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZYNRELEF Analytical Perspective

In-depth ZYNRELEF Market Assessment

This report provides a detailed market assessment of ZYNRELEF in Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

ZYNRELEF Clinical Assessment

The report provides the clinical trials information of ZYNRELEF for Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Postoperative Pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNRELEF dominance.
• Other emerging products for Postoperative Pain are expected to give tough market competition to ZYNRELEF and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYNRELEF in Postoperative Pain.
• Our in-depth analysis of the forecasted sales data of ZYNRELEF from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZYNRELEF in Postoperative Pain.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ZYNRELEF?
• What is the clinical trial status of the study related to ZYNRELEF in Postoperative Pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYNRELEF development?
• What are the key designations that have been granted to ZYNRELEF for Postoperative Pain?
• What is the forecasted market scenario of ZYNRELEF for Postoperative Pain?
• What are the forecasted sales of ZYNRELEF in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Postoperative Pain and how are they giving competition to ZYNRELEF for Postoperative Pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative Pain?